Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Comment by mercedesmanon Dec 21, 2023 8:08am
152 Views
Post# 35795321

RE:MBX Q4 Earnings

RE:MBX Q4 Earnings

Pretty much as I expected , with fiscal 2023 being the proverbial " kitchen sink of underwhelming sales" but also the "repositioning for future growth" year. 


Still shocking to see VTM go from $5M to zero! Is there no market or replenishment (ie  restocking of shelves for expired media) needed anywhere in Canada ?

2023 winds up with a $16.5 M top line with a reasonable target of $2M/ month or $24M annually going forward. Thats a potential  of 50% top line growth from here. Better forward Guidance will  likely be provided in January. $20 - $24M  for 2024?

The above does not include Kinlytic licensing Revenues which presumably are still 3-4 years out ( but which will be material and have yet (IMO) to be fully factored into the SP.

Short term milestone/ upfront payments for Kinlytic made in Q1 will also boosts revenues and margins for fiscal 2024. 

Good to have 2023 behind us finally. Onward and upward from here. 


MM 
 

 

<< Previous
Bullboard Posts
Next >>